BioCryst Pharmaceuticals | BCRX - Nettoeinkommen

Aktienkurs
9.71
Täglich Wechseln
0.01 0.05%
Monatlich
27.53%
Jährlich
20.56%
Q1 Prognose
9.41




Nettoeinkommen Veränderung Datum
Alnylam Pharmaceuticals USD 186.42M 64.66M 2025-12
BioCryst Pharmaceuticals USD 245.84M 232.95M 2025-12
Chugai Pharma JPY 128.41B 17.2B 2025-12
Daiichi Sankyo JPY 86.63B 41.32B 2025-12
DBV Technologies USD -33.16M 8.71M 2025-09
Enanta Pharmaceuticals USD -22.29M 93.76M 2024-12
Gilead Sciences USD 2.18B 869M 2025-12
GlaxoSmithKline GBP 636M 1.38B 2025-12
Glaxosmithkline GBP 846.06M 1.87B 2025-12
Incyte USD 299.28M 124.89M 2025-12
Ionis Pharmaceuticals USD -229M 100.39M 2025-12
Karyopharm Therapeutics USD -30.78M 1.29M 2024-12
Neurocrine Biosciences USD 209.5M 102M 2025-09
Novavax USD 17.53M 219.91M 2025-12
PTC Therapeutics USD -134.96M 150.86M 2025-12
Regeneron Pharmaceuticals USD 844.6M 615.4M 2025-12
Roche Holding CHF 5.47B 1.76B 2025-12
Sarepta Therapeutics USD -412.23M 232.28M 2025-12
Ultragenyx Pharmaceutical USD -129M 51.41M 2025-12
Vertex Pharmaceuticals USD 1.19B 108.2M 2025-12